AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Syntara Ltd

0.026

0.000

Volume:2.18M

Turnover:56.80K

Market Cap:51.01M

PE:-4.81

High:0.026

Open:0.026

Low:0.026

Close:0.026

52wk High:0.040

52wk Low:0.019

Shares:1.96B

Float Shares:1.00B

Volume Ratio:2.38

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.005

EPS(LYR):-0.005

ROE:-59.65%

ROA:-29.52%

PB:3.15

PE(LYR):-4.82

Loading ...

Overview Company News Filings

BRIEF-Syntara Seeks Trading Halt

Syntara Ltd - Trading Halt Pending Announcement on FDA Correspondence for Amsulostat Phase 2B Trial Protocol

THOMSON REUTERS

Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says

MT Newswires Live

Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SNT.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","market":"AU","secType":"STK","nameCN":"Syntara Ltd","latestPrice":0.026,"timestamp":1788156720000,"preClose":0.026,"halted":0,"volume":2184770,"delay":0,"changeRate":0,"nameEN":"Syntara Ltd","floatShares":1004676595,"shares":1961906275,"eps":-0.0054,"marketStatus":"Closed","change":0,"latestTime":"08-31 16:12:00 AEST","open":0.026,"high":0.026,"low":0.026,"amount":56804,"amplitude":0,"askPrice":0.027,"askSize":103226,"bidPrice":0.025,"bidSize":450000,"shortable":3,"etf":0,"ttmEps":-0.0054,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.026,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":2.378729,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"SNT.AU","preClose":0.026,"auctionPrice":0.026,"auctionVolume":2007057,"auctionTime":1788156591279,"referencePrice":0.026,"referenceTime":1788158520153,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156591279}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SNT.AU\",,,,,undefined,":{"symbol":"SNT.AU","floatShares":1004676595,"roa":"-29.52%","roe":"-59.65%","lyrEps":-0.005389,"volumeRatio":2.378729,"shares":1961906275,"dividePrice":0,"high":0.026,"amplitude":0,"preClose":0.026,"low":0.026,"week52Low":0.019,"pbRate":"3.15","psRate":"7.26","week52High":0.04,"institutionHeld":0,"latestPrice":0.026,"committee":0.626822,"eps":-0.0054,"divideRate":0,"volume":2184770,"delay":0,"ttmEps":-0.0054,"open":0.026,"prevYearClose":0.035,"prevWeekClose":0.026,"prevMonthClose":0.025,"prevQuarterClose":0.02,"fiveDayClose":0.027,"twentyDayClose":0.026,"sixtyDayClose":0.025},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-07-28","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1785160800000,"reportTimeType":"","actualEps":null},{"date":"2025-05-01","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746057600000,"name":null,"time":"","dateTimestamp":1746021600000,"actualEps":null},{"market":"AU","date":"2024-10-29","symbol":"SNT.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1730120400000,"reportTimeType":"pre","actualEps":null},{"date":"2024-04-30","symbol":"SNT.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714435200000,"name":null,"time":"","dateTimestamp":1714399200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNT.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630233023","title":"BRIEF-Syntara Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2630233023","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630233023?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:21","pubTimestamp":1777252899,"startTime":"0","endTime":"0","summary":"BRIEF-Syntara Seeks Trading HaltApril 27 (Reuters) - Syntara Ltd SNT.AX:TRADING HALT PENDING ANNOUNCEMENT ON FDA CORRESPONDENCE FOR AMSULOSTAT PHASE 2B TRIAL PROTOCOLFurther company coverage: SNT.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN4171CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","SNT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630476334","title":"Syntara Ltd - Trading Halt Pending Announcement on FDA Correspondence for Amsulostat Phase 2B Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2630476334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630476334?lang=en_us&edition=fundamental","pubTime":"2026-04-27 07:22","pubTimestamp":1777245767,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nFWN4171CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628349224","title":"Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2628349224","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628349224?lang=en_us&edition=fundamental","pubTime":"2026-04-17 11:58","pubTimestamp":1776398301,"startTime":"0","endTime":"0","summary":"Syntara's (ASX:SNT) Amsulostat drug candidate has a \"unique\" position in the myelofibrosis landscape and \"significant\" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620941432","title":"Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620941432","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620941432?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:19","pubTimestamp":1773883147,"startTime":"0","endTime":"0","summary":"Syntara  received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":24,"code":"91000000","status":"200"}]}}